PARSIPPANY, N.J. — Ferring Pharmaceuticals announced that it received approval from the Food and Drug Administration for new labeling of its fertility products Menopur and Bravelle. The update is a result of the Combine trial, which showed that both Menopur and Bravelle can be safely mixed and administered in a single injection.
"Ferring is excited to provide an IVF treatment option that requires fewer injections," said Nick Hart, Ferring's business unit head for U.S. Reproductive Health. "We are pleased with the FDA's response and look forward to offering physicians and patients the ability for customization and a simplified treatment protocol."
Menopur and Bravelle are both prescription medicines containing hormones that stimulate healthy ovaries to make eggs.